about
Diagnosing COPD: advances in training and practice - a systematic reviewDiagnosis, assessment, and phenotyping of COPD: beyond FEV₁Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled TrialT1 Relaxation Time in Lungs of Asymptomatic SmokersPrevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled studyCurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Sing Your Lungs Out-a community singing group for chronic obstructive pulmonary disease: a 1-year pilot study.Heterogeneity of asthma-COPD overlap syndromeReadiness for Delivering Digital Health at Scale: Lessons From a Longitudinal Qualitative Evaluation of a National Digital Health Innovation Program in the United Kingdom.Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema.Comprehensive respiratory assessment in advanced COPD: a 'campus to clinic' translational framework.Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.Biomarkers, the control panel and personalized COPD medicine.COPD Patients Have Short Lung Magnetic Resonance T1 Relaxation Time.Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease.Phenotyping Before Starting Treatment in COPD?Validity of the Asthma Control Test Questionnaire among Smoking Asthmatics.Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.AIT (allergen immunotherapy): a model for the "precision medicine".Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.The EASI model: A first integrative computational approximation to the natural history of COPDAsthma-COPD overlap is not a homogeneous disorder: further supporting data.Recognizable Clinical Subtypes of OSA across a Worldwide Sleep Center Population: A Cluster Analysis.Look back with (some) anger, and a lot of pleasure.An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?Metabolomics of exhaled breath condensate: a means for phenotyping respiratory diseases?The Challenges of Precision Medicine in COPD.Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.Development of matrix metalloproteinase-targeted probes for lung inflammation detection with positron emission tomography.Chronic obstructive pulmonary disease phenotypes. Past, present, and future.A novel statistical method for assessing effective adherence to medication and calculating optimal drug dosages.COPD: time to improve its taxonomy?
P2860
Q26751313-A3CDE9B2-2072-426C-B4F8-8E2725174177Q26764897-F915DAF5-EAEF-4E40-8BC7-55E6D96B6FD9Q27027259-5C94B41D-47AB-427F-A6B7-A1792E4BF74BQ35867300-B2C09DBC-B477-4EA8-91C7-4BBFB720328AQ35950823-8496B01E-0AA8-43B0-8347-4025931AB600Q36838758-6A90FD41-294C-4356-9208-2AE50E3A36D6Q36907742-5976502E-36BC-4AAC-8F1B-0675763CA007Q37627353-07A8608A-9583-4EEF-839D-7A7E40EFF566Q37669194-5FB2E917-DA9A-4532-8927-DBB2A0C29DA8Q37678162-D7B6A814-6022-447A-AF75-8B5D77D160C2Q38452733-5F2FEC60-35B2-43D4-B26A-ABD5739FCF38Q38474377-60AC0402-F70F-4D00-A364-3BFC964C6639Q38541559-6B95D90B-D4B3-45EA-A3D6-BAC01CD617FCQ38546748-DDA7DE87-D826-4319-96BB-D7EB5955482AQ38613003-FAA0C419-9BD0-4C7C-AD6C-E97FD5FEAB1AQ38710985-037CDE83-5710-44BA-B764-702E05751CFCQ39226768-3F9C47FD-A1AF-4531-900E-C3087CC77C7AQ40137696-366A4325-C5F8-44D5-B0BA-7B14A35221D1Q40598255-006AFAC5-2A30-472B-B3D4-D46F88848472Q41134553-0C28E3C5-1516-4BAB-BFED-D73C7C686EAAQ42662957-4E6EBBA5-2DA8-4F08-8D1E-FA792E9882F4Q42696087-510F3196-7C93-4800-8032-E631355B80F0Q47149724-079302BB-93ED-4556-9016-2756CEC23731Q47190109-F87B49C8-1F6C-4AE5-BC2D-58642F0B168CQ47659308-A180C238-17E0-4974-AD85-80106F667438Q47728819-7B4664F5-184F-4AB6-81FB-CECE5D03592EQ47862057-B1784149-AB78-486C-9DAA-7A147684AEC1Q47962475-E0626DF0-E8BA-4DCA-BBBC-2E96CB6FD5FBQ48013951-38A02844-B65D-4889-A656-186972065952Q48506067-8A0A2FB3-32AD-42AE-9331-35261F6E24A1Q48557466-B734B619-E36A-4ECB-84CE-3D3ED0C4CB39Q52574413-AA1879FD-EFB9-4B53-AD31-7E9B8B34385EQ54225498-53D42E9A-DAE4-461C-A1E1-55C2FBBF918C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The path to personalised medicine in COPD.
@en
type
label
The path to personalised medicine in COPD.
@en
prefLabel
The path to personalised medicine in COPD.
@en
P2860
P1433
P1476
The path to personalised medicine in COPD.
@en
P2093
Alvar Agusti
P2860
P304
P356
10.1136/THORAXJNL-2014-205507
P407
P577
2014-04-29T00:00:00Z